People with diabetes are at high risk of developing chronic kidney disease (CKD). RAAS inhibition with an ACE inhibitor or ARB have been a standard of care for most of these patients. Primary care clinicians are encouraged to use the latest evidence from antihyperglycemic agent trials demonstrating an improvement in CKD outcomes in managing their patients with type 2 diabetes.
This program is developed in collaboration with Partners in Progressive Medical Education (PPME), and endorsed by Diabetes Canada.
This program has received an educational grant or in-kind support from Abbott Diabetes Care, Astra Zeneca, Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc., Janssen, Novo Nordisk and Sanofi.